Extensive Dental Caries in Patients with Oral Chronic Graft-versus-Host Disease  by Castellarin, Paolo et al.
From the
Triest
Biolo
3Divis
Wom
of Or
Denta
Financial d
Correspon
ter, Br
and D
MA 0
Received F
 2012 Am
1083-8791
doi:10.101Extensive Dental Caries in Patients with Oral Chronic
Graft-versus-Host Disease
Paolo Castellarin,1 Kristen Stevenson,2 Matteo Biasotto,1 Anna Yuan,3
Sook-Bin Woo,3,4 Nathaniel Simon Treister3,4The oral cavity is one of the sites most frequently affected by chronic graft-versus-host disease (cGVHD)
after allogeneic hematopoietic cell transplantation (alloHCT) and can be a significant source of patient mor-
bidity due to both mucosal and salivary gland involvement. The development of dental decay is a potentially
devastating oral complication that has only rarely been reported in the transplantation literature. The pur-
pose of this study was to comprehensively characterize a cohort of patients with cGVHD who subsequently
developed extensive dental caries. A retrospective case-record review was conducted for patients who had
undergone alloHCT at Dana-Farber/Brigham and Women’s Cancer Center between 1990 and 2010 and
developed cGVHD-associated rampant dental decay. All patients underwent dental evaluation, involving
soft and hard tissue examination and dental radiography, before and after alloHCT. Any dental caries diag-
nosed at the pre-alloHCTevaluation were treated definitively, such that all patients were considered free
of caries at the time of admission for alloHCT. A total of 21 patients were identified, with a median time
of cGVHD onset of 5.4 months (range, 2.2-18.5 months) after alloHCT. All patients were diagnosed with
oral cGVHD, with 90% demonstrating mucosal involvement and 95% demonstrating salivary gland involve-
ment. Post-alloHCT dental evaluation was performed at a median of 22 months (range, 4-81) after alloHCT,
when 10 patients were diagnosed with gross caries and 8 patients had 4 or more affected teeth. Cervical and
interproximal patterns of dental caries were frequently diagnosed. The proportions of patients with gross
caries, one surface caries, and more than one surface caries (classified as 0, 1-3, and $4, respectively)
were significantly higher after alloHCT than before alloHCT, with at least 50% of patients experiencing an
increase. Patients with oral cGVHD who were free of caries at the time of transplantation developed exten-
sive areas of cervical decay at a median of less than 2 years after alloHCT. This is the first comprehensive
characterization of this severe late complication of alloHCTand oral cGVHD. Greater awareness by trans-
plantation oncologists and dentists, as well as more aggressive preventive measures, are needed, as are
further prospective studies to better elucidate the incidence of this complication, identify risk factors, and
evaluate the effectiveness of preventive interventions.
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Allogeneic hematopoietic cell transplantation (al-
loHCT) is a potentially curative cellular therapy for
the management of patients with hematologic malig-
nancies and bone marrow failure syndromes [1]. De-
spite prophylaxis strategies, chronic graft-versus-host
disease (cGVHD)develops in 25%to45%of recipients
undergoing alloHCT from a matched related sibling
and in up to 40% to 70% of unrelated donor recipients
[2].Mediatedprimarily by alloreactiveTcells, cGVHD
resembles a range of autoimmune and immune-
mediated conditions producing a wide range of clinical
presentations and symptomatology, with a significant
impact on overall quality of life [3-5]. Although
patients with cGVHD are at lower risk of relapse
compared with those without cGVHD, cGVHD
remains the chief cause of nonrelapse mortality due to1573
Figure 1. Oral cGVHD-associated pattern of dental caries. (A-D) Extensive cervical caries affecting nearly all teeth, with some teeth with gross
advanced caries and generalized breakdown (shown in D). Early demineralization changes, with a white appearance at the cervical margin, can be
appreciated in (A).
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obliterans of the lungs) and infections [6,7].
The oral cavity is one of the sites most frequently
affected by cGVHD and can be a significant
source of patient morbidity [8-11]. The salivary
glands are a major target of cGVHD, characterized
histopathologically by a periductal lymphocytic
infiltrate with a predominance of CD81 over CD41
T cells expressing HLA-DR, resulting in both quanti-
tative and qualitative deficiencies of the major and mi-
nor glands [12,13]. A reducted saliva flow rate in
patients with cGVHD has been reported in several
studies, and reported biochemical and immunological
compositional alterations include elevated salivary
concentrations of Na, Mg, lysozyme, epidermal
growth factor, total protein, albumin, and IgG and
decreased levels of IgM and IgA [13-15]. Patients
with salivary gland cGVHD report symptoms of
xerostomia, characterized by frequent thirst; difficulty
eating, speaking, and swallowing; oral sensitivity; and
changes in taste sensation [16].
To date, there have been few reports in the litera-
ture of dental caries developing as a complication of
alloHCT and cGVHD [17,18]. Heimdahl et al. [17]
evaluated 27 patients at 1 year after alloHCT and
found a wide range of caries status, with no new caries
in 51% of patients and rampant caries in nearly all
teeth in 37%. Rampant caries were more frequent in
patients with a history of prolonged hospitalization,
compromised general condition, impaired salivary
function, restricted dietary intake, and impaired oral
hygiene maintenence [17]. Cervical dental decay(ie, dental caries along the gingival margin; Figure 1)
is seen infrequently in the general population in the
absence of severe salivary gland hypofunction or gross
neglect, and in the clinical context of patients undergo-
ing alloHCTwithout known preexisting salivary gland
disease (eg, Sj€ogren syndrome, previous radiation
therapy to the head/neck) and/or a high caries rate,
there is a very low likelihood that the presence of this
pattern of decay can be attributed to any other etiology
other than oral cGVHD-associated changes. Despite
this being a potentially devastating oral complication,
it remains largely underrecognized within the hemato-
poietic cell transplantation community. The objective
of the present study was to comprehensively evaluate
a cohort of patients with cGVHD who developed ex-
tensive rampant dental caries in terms of risk factors,
clinical features, and management.METHODS
A retrospective case-record review was conducted
for patients who had undergone alloHCT at Dana-
Farber/Brigham and Women’s Cancer Center
(DFBWCC) between 1990 and 2010 and developed
cGVHD-associated rampant dental decay. These
patients were defined as those who were caries-free
before alloHCT and were subsequently diagnosed
with extensive areas of cervical decay after alloHCT.
Salivary gland cGVHD was diagnosed based on
clinical signs and symptoms; minor salivary gland bi-
opsies were not performed [19]. Demographic and
transplantation-related data collected included age,
Figure 2. Representative bitewing radiographic features of oral cGVHD-associated dental caries. (A-D) Interproximal radiolucent changes affecting the
crown and root surfaces (see B in particular), in some cases at the margins of restorations (A, lower first molar). Very advanced caries are shown in (D),
which corresponds to the same patient in Figure 1D.
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regimen, donor matching and stem cell source, acute
GVHD grade, date of initial cGVHD diagnosis, and
cGVHD target organ involvement and therapy. Oral
cGVHD features and management were recorded
as well.
Pre-alloHCT Dental Evaluation
All patients underwent dental evaluation before
and after alloHCT at DFBWCC. Pretransplantation
dental evaluation included a formalized compre-
hensive oral soft and hard tissue examination and
a full-mouth series of dental radiographs, typically
completed within 3 months before alloHCT. Patients
were evaluated either at the DFBWCC Division of
Oral Medicine and Dentisty or at their local dentist
office according to a formal off-site evaluation pro-
gram [19]. All identified dental caries were managed
definitively by restorative dentistry, endodontic ther-
apy, or extraction, as indicated, such that patients
were considered caries-free at the time of alloHCT.
All patients were examined by the Oral Medicine Ser-
vice at DFBWCC at the time of hospital admission for
alloHCT to review and confirm their oral status.
Post-AlloHCT Dental Evaluation
Patients were referred to the Division of Oral
Medicine and Dentistry at DFBWCC for evaluation
and management of oral cGVHD. In some cases, the
presence of dental caries was the primary reason for re-
ferral, whereas in other cases, the dental caries wereidentified on examination. All patients were evaluated
by 1 of 2 oral medicine specialists (NT or SW). The
date of diagnosis was defined as the date of the initial
oral medicine consultation when rampant caries were
diagnosed clinically. All patients were queried about
dry mouth symptoms [20].
Evaluation of Dental Caries
Dental caries data were collected using a standard-
ized form. Caries were detected based on standard
clinical and radiographic criteria (Figure 2). Tooth
surfaces (occlusal, incisal, interproximal, cervical, and
lingual) were evaluated for the presence of caries, and
individual teeth were noted for the number of surfaces
involved. Teeth were further classified as having gross
caries when clinically evident caries were seen on
$50% of the tooth surfaces. Teeth with gross caries
were considered nonrestorable, and treatment was
planned for extraction.
Statistical Analyses
Descriptive statistics, including frequency (per-
centage) for categorical data and median and range
for continuous measures, were used to summarize
the data. Pre- and post-alloHCT measures were com-
pared by a 2-sided exact test of marginal homogeneity
for ordered categories using StatXact version 9.0 (Cy-
tel Studio, Cambridge, MA) and were considered sig-
nificant at the P 5 .05 level. This study was approved
by the Dana-Farber/Harvard Cancer Center’s Office
for Human Research Subjects.
Table 1. Patient Characteristics
Number 21
Age, years, median (range) 45 (13-67)
Male sex, n (%) 15 (71)
Conditioning, n (%)
Myeloablative 15 (71)
Nonmyeloablative 6 (29)
Donor type, n (%)
Matched related 5 (24)
Matched unrelated 16 (76)
Diagnosis, n (%)
AML 7 (33)
ALL 5 (24)
MDS 4 (19)
CLL 3 (14)
CML 1 (5)
NHL 1 (5)
Grade II-IV acute GVHD, n (%) 8 (38)
Time to cGVHD, months, median (range)a 5.4 (2.2-18.5)
cGVHD NIH classification, n (%)
De novo 6 (29)
Quiescent 9 (43)
Progressive 6 (29)
cGVHD organ involvement, n (%)b
Oral 21 (100)
Skin 18 (86)
Liver 11 (52)
Eyes 11 (52)
Gut 5 (24)
Lungs 5 (24)
Vaginal 3 (14)
Time to oral evaluation, months, median (range)a 22 (4-81)
Number of systemic therapies for cGVHD at time of caries
diagnosis, median (range)
3 (1, 5)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloge-
nous leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin
lymphoma.
aCalculated from the date of alloHCT.
bMultiple sites are possible, so frequencies do not add up to 21, and per-
centages do not add up to 100%.
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Twenty-one patients who underwent allo-HCT
at DFBWCC between 1990 and 2010 were included
in the analysis (Table 1). All patients underwent
alloHCT for management of underlying hematologic
malignancies, with the majority receiving myeloabla-
tive conditiong regimens and matched unrelated
donor stem cell grafts. All patients were affected by
cGVHD, with a median time of onset of 5.4 months
(range, 2.2-18.5 months) after alloHCT. The majority
of patients were managed systemically with prednisone
and tacrolimus (Table 2).Table 2. Systemic cGVHD-Associated Therapies in the 21
Patients at the Initial Caries Diagnosis Visit After AlloHCT
n (%)
Prednisone 20 (95)
Sirolimus 11 (52)
Mycophenolate mofetil 11 (52)
Tacrolimus 14 (67)
Cyclosporine 4 (19)
Rituximab 4 (19)
Extracorporeal photochemotherapy 2 (10)
Low-dose IL-2 [28] 2 (10)Nineteen patients (90%) were diagnosed with oral
mucosal cGVHD and reported a range of pain symp-
toms; most of these patients weremanaged with a com-
bination of topical corticosteroids and topical
tacrolimus (Table 3). All but one patient exhibited
clinical signs of salivary gland cGVHD, with nearly
40% reporting severe dryness with a score of $8 on
a scale of 0 to 10, with 10 being the worst dryness pos-
sible. More than half reported having too little saliva
and needing to sip liquids to swallow dry food. The
majority of patients were prescribed sialogogue ther-
apy for management of dry mouth symptoms, and all
received prescriptions for topical fluoride gel.
Post-alloHCT dental evaluation was performed at
a median of 22 months after transplantation (Table 4).
Uniformily, there were significantly more caries diag-
nosed and more extensive dental requirements at the
post-alloHCT visit compared with the pre-alloHCT
visit. For example, at the pre-alloHCT visit, 4 patients
were diagnosed with gross caries, all with less than 4
affected teeth, and these were all treated definitively.
At the post-alloHCT visit, 10 patients were diagnosed
with gross caries, with 8 patients presenting with 4 or
more affected teeth. Whereas 4 patients required
extractions (of 1-3 teeth) before alloHCT, 10 patients
required extractions post-alloHCT, 7 of whom (33%)
required extraction of 4 or more teeth.
Cervical and interproximal patterns of dental car-
ies were frequently diagnosed at the post-alloHCT
visit (Table 5). At least half of the teeth with 1 surface
caries demonstrated cervical or interproximal decay,
with 6 patients having 4 or more teeth with cervical
caries, and 8 patients having 1 to 3 teeth with inter-
proximal surface caries. In teeth with more than 1 sur-
face affected, 12 patients had 4 or more teeth with
interproximal surface caries, and 7 patients had 4 or
more teeth with cervical decay. With respect to the
percentage changes in the number of patients with 1
surface caries, more than 1 surface caries, and gross
caries, all categories demonstrated a statistically signif-
icant difference from pre- to post-alloHCT, with at
least 50% of patients in each category demonstrating
an increase (Figure 3).DISCUSSION
The present study evaluated 21 patients who
had undergone alloHCT and developed cGVHD-
associated rampant dental caries. Significantly more
caries were diagnosed, andmore extensive dental treat-
ment was required at the post-alloHCT visit com-
pared with before alloHCT, and cervical and
interproximal patterns of dental caries were frequently
diagnosed. The time to diagnosis of rampant caries
was very short (eg, 1 year or less) in many cases, sug-
gesting that this may be a relatively early complication
that can be screened for during routine clinical
Table 3. Oral cGVHD Clinical History of the 21 Patients
Number of patients 21
Oral mucosal disease, n (%) 19 (90)
Oral cGVHD stage, n (%)
0 5 (24)
I 4 (19)
II 9 (43)
III 1 (5)
NA 2 (10)
Topical therapy for mucosal disease, n (%)a
Corticosteroids 17 (81)
Tacrolimus 13 (62)
Worst pain score on a scale of 0-10, n (%)
0-2 8 (38)
3-5 3 (14)
6-8 6 (29)
NA 4 (19)
Salivary gland disease, n (%) 20 (95)
Salivary gland disease management, n (%)a
Sialogogue therapy 13 (62)
Over-the-counter oral moisturizing agents 14 (67)
Topical fluoride 21 (100)
Worst dryness score on a scale of 0-10, n (%)
0-3 4 (19)
4-7 5 (24)
8-10 8 (38)
NA 4 (19)
Xerostomia questions, ‘‘yes’’ response, n (%)
Do you sip liquids to help you swallow dry foods? 12 (57)
Do you have difficulty swallowing any foods? 6 (29)
Does your mouth feel dry when eating a meal? 8 (38)
Do you seem to have too little saliva in your mouth? 11 (52)
NA indicates not available.
aMultiple regimens are possible, and so frequencies do not add up to 21,
and percentages do not add up to 100%.
Table 4. Dental Findings and Procedures Before and After
AlloHCT
Pre-AlloHCT Post-AlloHCT
Number of patients 21 21
Gross caries, n (%)
0 17 (81) 10 (48)
1-3 4 (19) 2 (9)
$4 0 (0) 8 (38)
NA 0 (0) 1 (5)
One surface caries, n (%)
0 13 (62) 2 (9)
1-3 5 (24) 4 (18)
$4 3 (14) 10 (48)
NA 0 (0) 5 (24)
More than one surface caries, n (%)
0 13 (62) 3 (14)
1-3 4 (19) 5 (24)
$4 4 (19) 9 (43)
NA 0 (0) 4 (18)
Dental procedures, n (%)
One surface restoration
0 15 (71) 5 (24)
1-3 5 (24) 5 (24)
$4 1 (5) 7 (33)
NA 0 (0) 4 (18)
More than one surface restoration
0 14 (67) 5 (24)
1-3 4 (19) 4 (18)
$4 3 (14) 9 (43)
NA 0 (0) 3 (14)
Extraction
0 17 (81) 9 (43)
1-3 4 (19) 3 (14)
$4 0 (0) 7 (33)
NA 0 (0) 2 (9)
NA indicates not available.
Caries were classified as one surface, more than one surface, or gross
caries (more than 50% of the tooth involved). Patients were categorized
into 3 groups according to the number of teeth affected with caries (0, 1-
3, $4). Patients affected by one surface caries underwent one surface
restoration, those affected by more than one surface caries underwent
more than one surface restoration, and those affected by gross caries
uderwent extraction of the involved tooth.
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caries, this finding suggests that patients should
undergo routine dental examinations with bitewing
radiographs in the early follow-up period, no later
than 6 months to 1 year after alloHCT.
The salivary glands are a major and likely highly
underrecognized target of cGVHD, contributing to
both quantitiative and qualitative salivary changes.
This results in a number of adverse changes that
increase the risk of dental caries, including overall re-
duced flow and cleansing ability, reduced antimicro-
bial activity, compromised buffering capacity, and
a decreased rate of enamel and dentin remineralization
[13,16,21,22]. A 55% to 90% reduction in saliva flow
has been reported in patients with cGVHD, which
further exacerbates the consequences of qualitative
changes [20,23]. Several previous studies have
examined the potential roles of cariogenic bacteria
(Streptococcus mutans and lactobacilli, the primary
bacteria responsible for mediating dental caries) in
patients after alloHCT, with some finding increased
colony counts and others reporting no change or
even decreasesd counts [17,24,25]. Imanguli et al.
[16] found no difference in salivary flow rates between
patients with and without mucosal disease, as well as
no correlation between flow rate and severity of oral
mucosal disease, indicating that these appear to be
2 clinically distinct oral cGVHD manifestations.Furthermore, salivary dysfunction had a much greater
impact than mucosal disease on oral cavity-specific
quality-of-life scores and morbidity [16]. Management
of salivary gland cGVHD includes symptomatic strat-
egies (eg, bland rinses, frequent sips of water, artificial
saliva or coating agents that moisten the mouth, sugar-
less candies), prescription sialogogue therapy, and an-
ticaries measures [10,22,23]. Approaches to preventing
dental caries include maintenance of scrupulous oral
hygiene, topical fluoride (rinses, gels and varnishes),
calcium/phosphate-based remineralizing agents, and
reduced dietary intake of refined carbohydrates
[10,22,26,27].
There are only 2 reports in the literature describ-
ing the development of rampant caries in patients
with cGVHD. Heimdahl et al. [17] reported a wide
range of dental caries status in 27 patients at 1 year
after alloHCT, with 14 patients demonstrating no
new carious lesions and 10 patients exhibiting rampant
caries on nearly all teeth. The clinical appearance of
the decay varied from early decalcification lesions to
Table 5. Post-AlloHCT Dental Examination Findings by Sur-
face Location
Cervical
Surface
Interproximal
Surface
Number of patients 21 21
One surface caries, n (%)
0 5 (24) 5 (24)
1-3 5 (24) 8 (38)
$4 6 (29) 3 (14)
NA 5 (24) 5 (24)
More than one surface caries, n (%)
0 5 (24) 3 (14)
1-3 3 (14) 2 (10)
$4 7 (33) 12 (57)
NA 6 (29) 4 (19)
NA indicates not available.
Caries were classified as involving either one tooth surface or more than
one surface. Patients were categorized into 3 groups according to the
number of teeth affected with caries (0, 1-3, or $4).
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No single factor was correlated with the development
of rampant caries; however, caries were more frequent
in patients with a history of acute GVHD, prolonged
hospitalization, poor general health, impaired oral
hygiene, and reduced salivary function [17]. Curtis
and Caughman [18] reported a 29-year-old female
with severe oral mucosal cGVHD and rampant caries
who experienced complete resolution of mucosal
lesions after complete tooth extraction. The authors
hypothesized that the mucosal improvement was due
to removal of sharp edges that might have been contin-
uously irritating the tissue.
Despite its retrospective case series nature, a sign-
ificant strength of this study is related to the fact that
all patients at our center undergo comprehensive
dental screening and clearance before admission for
alloHCT. Because of this screening process and con-
firmation of the caries-free status of all patients at
the time of alloHCT, we were able to measure the
incidence of new caries after alloHCT. The lack of
a control group precludes us from evaluating associ-
ated risk factors, and incidence and prevalence figuresFigure 3. Percentage change in the number of caries and extractions
from before alloHCT to after alloHCT.in this patient population remain unknown. Because
this study focused exclusively on patients with exten-
sive dental findings and did not measure the burden
of dental disease in all patients after alloHCT, the
overall extent and impact of dental caries in this patient
population is unclear, but likely is significant. In addi-
tion, because most of the patients were evaluated but
did not receive dental care at our center, follow-up
on the actual dental treatment provided was not
available.
In the present study, we have shown that cGVHD
dental caries may be an early and potentially serious
oral complication in patients after alloHCT.
In addition to pain, infection, and dental treatment–
associated costs, multiple extractions can result in
compromised esthetics and impair the ability to eat.
In addition to proper dental screening and clearance
before undergoing alloHCT, patients should be
followed carefully after alloHCT for dry mouth symp-
toms and routine oral cavity examinations for evidence
of dental changes, including enamel demineralization
and frank caries. All patients should undergo a dental
evaluation at 6 to 12months post-alloHCT and at least
every 6months thereafter. Better training of transplan-
tation physicians and nurses should result in earlier
and improved diagnosis and intervention. Future
prospective studies evaluating clinical, radiographic,
and salivary changes and their impact on quality of
life, as well as prevention protocols, will provide
a more clear picture of the extent and burden of this
oral complication of alloHCT.ACKNOWLEDGMENTS
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